As demonstrated by Hirose et al., the use of such systems for the administration of bioactive proteins, such as bFGF and beta interferon (IFN-β), is a promising strategy for the treatment of proliferative vitreoretinopathy, with significant advantages compared to other models [166]. The gene discussed is IFNB1; the disease is CAPN5-related vitreoretinopathy.